Validation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain Tissue
Phase of Trial: Phase IV
Latest Information Update: 07 Aug 2014
Price : $35 *
At a glance
- Drugs Ioflupane 123I (Primary)
- Indications Parkinson's disease
- Focus Diagnostic use
- Sponsors GE Healthcare
- 15 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 11 Jul 2014 Planned End Date changed from 1 Apr 2016 to NULL.
- 11 Jul 2014 Planned primary completion date changed to 1 Apr 2016.